Cannabix Technologies to Exhibit at National Safety Council (NSC) Safety Congress and Expo, Denver Colorado
Globenewswire· 2025-09-08 20:30
VANCOUVER, British Columbia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report its participation in the NSC Safety Congress & Expo, taking place September 15–17, 2025 in Denver, Colorado. The NSC Safety Congress & Expo is the world’s largest annual event dedicated to workplace safety, health, and environmental professionals and will have thousan ...
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
Globenewswire· 2025-09-08 20:30
核心观点 - 公司获得欧盟CE标志批准 推出第七代ReWalk个人外骨骼系统 预计将推动欧洲市场商业采用和收入增长 [1][2] 产品技术 - 第七代ReWalk具备云端连接 按钮控制 可定制行走速度 以及台阶路缘石无缝激活功能 [1] - 产品专为脊髓损伤患者设计 旨在提供卓越控制力和真实环境移动能力 [2] 市场布局 - 欧洲市场占公司外骨骼销售额约40% 德国为全球第二大个人外骨骼市场 [1][2] - 德国子公司Lifeward GmbH已建立广泛报销机制 与BARMER等主要保险商签订供应合约 覆盖德国法定医保人群的45% [1][2] - 公司以德国报销模式为范本 正逐步复制至美国等其他战略市场 [2] 公司背景 - 公司自2001年成立 在美以德三国设有运营机构 产品线涵盖ReWalk外骨骼 AlterG反重力系统 ReStore外骨骼服及MyoCycle FES系统 [3] - 自2010年获首张CE认证以来 历代ReWalk产品持续供应欧洲市场 [2]
CorMedix Announces Strategic Minority Investment in Talphera
Globenewswire· 2025-09-08 20:30
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera’s concurrently announced private placement financing. Talphera expec ...
Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy
Globenewswire· 2025-09-08 20:30
Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for human therapies and IsoPet® for veterinary applications) Advancing Targeted Cancer Therapies The therapeutic ratio is the amount of radiation delivered to a tumor compared to surrounding healthy tissue and is a critical measure of treatment precision. A high therapeutic ratio minimizes collateral damage while ma ...
Edible Garden’s Kick. Sports Nutrition, Sports Nutrition Product of the Year, Introduces Clean Labeled Creatine, Pre and Post Workout Recovery Products, and Bold Flavors Featuring Dubai Chocolate and Pistachio Ice Cream at ECRM
Globenewswire· 2025-09-08 20:30
BELVIDERE, NJ, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced it will showcase its innovative, award-winning Kick. Sports Nutrition line, recently recognized as the 2025 Sports Nutrition Product of the Year by the Mindful Awards, at ECRM’s Vitamin, Weight Management & Sports Nutrition Session, taking p ...
REPEAT: CleanCore Solutions Announces Closing of $175,000,420 Private Placement
Globenewswire· 2025-09-08 20:30
Establishes the official Dogecoin Treasury of the Dogecoin Foundation and its Newly Established Corporate Arm, the House of Doge The transaction consisted of marquee institutional and crypto native investors including, but not limited to, MOZAYYX, Pantera, GSR, FalconX and Borderless OMAHA, Neb., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”), today announced the closing of its private investment in public equity (PIPE) financing. The offeri ...
UMeWorld Expands Growth Strategy with DAGola China Launch, Biofuel Pilot Plant, and Future SAF Potential
Globenewswire· 2025-09-08 20:30
MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF), a public company engaged in functional nutrition and sustainable biofuel innovation, today provided a comprehensive corporate update. UMeWorld operates a dual-growth platform powered by a single proprietary enzymatic technology. This breakthrough process enables the Company to deliver both DAGola™ functional cooking oils, clinically validated to improve metabolic health, and enzymatic biofuels, designed to convert low-cost feedstocks i ...
I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments
Globenewswire· 2025-09-08 20:30
Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to followReiterates expectations to report topline givastomig Phase 1b dose expansion data in Q1 2026Plans to broaden the 1L development strategy into locally advanced gastric cancer as well as other Claudin 18.2-positive tumor types, including biliary tract cancer (BTC) and pancreatic ductal adenocarc ...
Statement by the Board of Directors of CoinShares regarding the joint merger plan with Odysseus Holdings, Vine Hill Capital Investment Corp., Odysseus Holdings Limited and others
Globenewswire· 2025-09-08 20:29
CoinShares International Limited (“CoinShares”) Vine Hill Capital Investment Corp., a special purpose acquisition company listed on the Nasdaq Stock Market (“Vine Hill”), and Odysseus Holdings Limited, a newly formed Jersey entity, (“Odysseus Holdings”)1 today jointly announce that CoinShares, Vine Hill and Odysseus Holdings have agreed on a joint merger plan including a court-sanctioned Scheme of Arrangement (as defined below) under Jersey Law between CoinShares and its shareholders (such joint merger plan ...
Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System
Globenewswire· 2025-09-08 20:28
LIBERTY Endovascular Robotic System * Microbot Medical® Receives FDA 510(k) Clearance for Its LIBERTY® Endovascular Robotic System Accelerated Launch Readiness Plans Position Company for Commercialization during Q4 2025 The Company’s Initial Addressable Market Includes Approximately 2.5 Million Peripheral Endovascular Procedures in the U.S. Annually CEO, President & Chairman to Present Live Webcast at the H.C. Wainwright Annual Investor Conference on September 9, 2025, at 9 AM ET. HINGHAM, Mas ...